We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

40 hedge funds and large institutions have $4.91M invested in Viracta Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 40 → 40 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

49% less capital invested

Capital invested by funds: $9.58M → $4.91M (-$4.67M)

Holders
40
Holders Change
–
Holders Change %
0%
% of All Funds
0.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
8
Reduced
9
Closed
2
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$24.3K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$14.3K
3
Morgan Stanley
Morgan Stanley
New York
+$13K
4
Renaissance Technologies
Renaissance Technologies
New York
+$12K
5
TRCT
Tower Research Capital (TRC)
New York
+$2.97K

Top Sellers

Rank Fund Capital Flow
1
MCM
MAI Capital Management
Ohio
-$266K
2
Citadel Advisors
Citadel Advisors
Florida
-$35.5K
3
UBV
United Bank (Virginia)
Virginia
-$25.7K
4
BlackRock
BlackRock
New York
-$24.2K
5
LCM
Laurion Capital Management
New York
-$10.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCMC
26
Planning Capital Management Corporation
Pennsylvania
$3.95K – – –
Simplex Trading
27
Simplex Trading
Illinois
$3K +$1.94K +2,453 +50%
RM
28
RP Management
New York
$2K – – –
IWP
29
IAG Wealth Partners
Wisconsin
$1.63K – – –
Barclays
30
Barclays
United Kingdom
$1.45K – – –
UBS Group
31
UBS Group
Switzerland
$920 +$1.26K +1,595 +1,679%
JP Morgan Chase
32
JP Morgan Chase
New York
$392 – – –
ITIM
33
Indiana Trust & Investment Management
Indiana
$109 – – –
Wells Fargo
34
Wells Fargo
California
$93 -$169 -214 -56%
NA
35
NewEdge Advisors
Louisiana
$8 – – –
PA
36
Parallel Advisors
California
$4 – – –
AA
37
Addison Advisors
Vermont
$3 – – –
PO
38
Private Ocean
California
$2 +$2 +3 New
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$1 – – –
UBV
40
United Bank (Virginia)
Virginia
– -$25.7K -25,200 Closed
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
– -$1.27K -1,611 -78%
NS
42
NBC Securities
Alabama
– -$1K -1,400 Closed
1
2

VIRX Hedge Fund Activity: Q2 2024 in Review

40 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2024, worth a combined $4.91M — down 49% from $9.58M a quarter earlier.

Fund positioning in VIRX was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 9 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $24.3K. The largest seller was MAI Capital Management, cutting an estimated $266K.

  • 40 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $4.91M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2024, down 49% quarter-over-quarter.
  • 2 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2024 and 2 closed out, a net change of 0 holders.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2024 was Virtu Financial, an estimated $24.3K added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2024 was MAI Capital Management, an estimated $266K sold.

Based on aggregated 13F filings for Q2 2024.